Oncotarget is an organization that publishes research type papers concerning Oncology as well as Cancer Research. In addition, Oncotarget also publishes well researched papers concerning Endocrinology as well as Pathology.Essentially, Oncotarget publishes medical material which is helpful to physicians as well as medical students. Such material can provide new insight into medical treatment as well as potential cures which are not known to the public.There are other areas in which Oncotarget publishes updated material. Other areas of research and interest include Cell Diseases and Endocrine Immunology.
You may also contact Oncotarget directly for information regarding article submission guidelines, publication fees as well as publishing policies. In addition, manuscripts may be submitted concerning a variety of medical topics. Once manuscripts are submitted a review process takes place which could take up to 3 months.Group Authorship opportunities are also available through Oncotarget. Essentially, one or more authors must be identified once a manuscript is approved for publication. In addition, if more than one author is identified and associated with a particular article then all parties names will be listed as the original creator and or publisher of the article.
*Article Submission Guideline Information:
Article submissions require complete and updated contact information, identifiable sources (where information was gathered), as well as reason for wanting to publish a specific article. Some articles are published for research purposes. Some articles are published and used as teaching tools for undergraduate medical students.There are special policies concerning any animal related articles. Articles that may involve any form of animal testing must go through an intensive approval and or verification process. All testing must be in accordance with current laws regarding animal testing.Finally, Oncotarget is a useful resource for medical professionals. Oncotarget gives others the opportunity to become part of the Oncotarget community through new article submission.